BRAF V600E CRC BEACON — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGI CancersBRAF V600E CRC BEACONSCE Medical Oncology

A 65-year-old man with mCRC has BRAF V600E mutation (~8-10% of mCRC). What is the NICE-approved targeted regimen?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Encorafenib + cetuximab (BEACON CRC trial) — single-agent BRAF inhibition is ineffective in CRC due to feedback EGFR reactivation

BEACON CRC: encorafenib + cetuximab showed ORR ~20%, OS ~9 vs ~5.4 months vs standard chemo. Single-agent BRAF inhibition fails in CRC due to EGFR feedback — dual BRAF+EGFR blockade is required.

Reference: NICE TA868; BEACON CRC Kopetz et al NEJM 2019